Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc.verified

DRMA

Price:

$1.1371

Market Cap:

$2.32M

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered...[Read more]

Industry

Biotechnology

IPO Date

2021-08-13

Stock Exchange

NASDAQ

Ticker

DRMA

The Enterprise Value as of November 2024 (TTM) for Dermata Therapeutics, Inc. (DRMA) is -3823196.00

According to Dermata Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -3823196.00. This represents a change of -178.09% compared to the average of 4.90M of the last 4 quarters.

Dermata Therapeutics, Inc. (DRMA) Historical Enterprise Value (quarterly & annually)

How has DRMA Enterprise Value performed in the past?

The mean historical Enterprise Value of Dermata Therapeutics, Inc. over the last ten years is 312.31M. The current -3823196.00 Enterprise Value has changed -222.42% with respect to the historical average. Over the past ten years (40 quarters), DRMA's Enterprise Value was at its highest in in the December 2020 quarter at 10.38B. The Enterprise Value was at its lowest in in the September 2024 quarter at -3594076.80.

Quarterly (TTM)
Annual

Average

312.31M

Median

206.58M

Minimum

-5663035.00

Maximum

651.40M

Dermata Therapeutics, Inc. (DRMA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Dermata Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0.57%

Maximum Annual Enterprise Value = 651.40M

Minimum Annual Increase = -109.20%

Minimum Annual Enterprise Value = -5663035.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023-5663035.00-109.20%
202261.55M-70.20%
2021206.58M-68.29%
2020651.40M0.57%

Dermata Therapeutics, Inc. (DRMA) Average Enterprise Value

How has DRMA Enterprise Value performed in the past?

The current Enterprise Value of Dermata Therapeutics, Inc. (DRMA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

87.49M

5-year avg

312.31M

10-year avg

312.31M

Dermata Therapeutics, Inc. (DRMA) Enterprise Value vs. Peers

How is DRMA’s Enterprise Value compared to its peers?

Dermata Therapeutics, Inc.’s Enterprise Value is greater than Zura Bio Limited (-9969663.00), less than Phio Pharmaceuticals Corp. (-2783607.00), less than Sonnet BioTherapeutics Holdings, Inc. (-907921.00), less than 180 Life Sciences Corp. (4.73M), less than Cardio Diagnostics Holdings, Inc. (9.47M), less than Windtree Therapeutics, Inc. (5.97M), less than Ensysce Biosciences, Inc. (4.65M), less than Panbela Therapeutics, Inc. (4.75M), less than Baudax Bio, Inc. (7.73M), less than ZyVersa Therapeutics, Inc. (2.53M), less than Revelation Biosciences, Inc. (-3300245.00), less than Navidea Biopharmaceuticals, Inc. (-2504975.00), less than Altamira Therapeutics Ltd. (909.70K), less than Immix Biopharma, Inc. (30.53M), less than Hepion Pharmaceuticals, Inc. (5.35M), greater than AVROBIO, Inc. (-85302404.00), less than eFFECTOR Therapeutics, Inc. (4.74M),

Build a custom stock screener for Dermata Therapeutics, Inc. (DRMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dermata Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dermata Therapeutics, Inc. (DRMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dermata Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Dermata Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Dermata Therapeutics, Inc. (DRMA)?

What is the 3-year average Enterprise Value for Dermata Therapeutics, Inc. (DRMA)?

What is the 5-year average Enterprise Value for Dermata Therapeutics, Inc. (DRMA)?

How does the current Enterprise Value for Dermata Therapeutics, Inc. (DRMA) compare to its historical average?